期刊
EUROPEAN SURGICAL RESEARCH
卷 54, 期 3-4, 页码 162-177出版社
KARGER
DOI: 10.1159/000369552
关键词
Hepatocyte transplantation; Human hepatocytes; Metabolic liver disease; Cell-based therapy; Regenerative medicine
类别
资金
- Torsten och Ragnar Soderberg Stiftelse
- Swedish Research Council
- Ruth and Richard Julins Foundation
Since the first human hepatocyte transplants (HTx) in 1992, clinical studies have clearly established proof of principle for this therapy as a treatment for patients with acquired or inherited liver disease. Although major accomplishments have been made, there are still some specific limitations to this technology, which, if overcome, could greatly enhance the efficacy and implementation of this therapy. Here, we describe what in our view are the most significant obstacles to the clinical application of HTx and review the solutions currently proposed. The obstacles of significance include the limited number and quality of liver tissues as a cell source, the lack of clinical grade reagents, quality control evaluation of hepatocytes prior to transplantation, hypothermic storage of cells prior to transplantation, preconditioning treatments to enhance engraftment and proliferation of donor cells, tracking or monitoring cells after transplantation, and the optimal immunosuppression protocols for transplant recipients. (C) 2015 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据